BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

621 related articles for article (PubMed ID: 20190186)

  • 1. Re: Prostate cancer diagnosis and treatment after the introduction of prostate-specific antigen screening: 1986-2005.
    Belpomme D; Irigaray P
    J Natl Cancer Inst; 2010 Apr; 102(7):506-7. PubMed ID: 20190186
    [No Abstract]   [Full Text] [Related]  

  • 2. Why are a high overdiagnosis probability and a long lead time for prostate cancer screening so important?
    Barry MJ; Mulley AJ
    J Natl Cancer Inst; 2009 Mar; 101(6):362-3. PubMed ID: 19276451
    [No Abstract]   [Full Text] [Related]  

  • 3. Solving the overdiagnosis dilemma.
    Esserman L; Thompson I
    J Natl Cancer Inst; 2010 May; 102(9):582-3. PubMed ID: 20413743
    [No Abstract]   [Full Text] [Related]  

  • 4. [Mass screening for prostate cancer is the best approach to early diagnosis and treatment of prostate cancer].
    Zhao XJ; Kong XB; Wang WH
    Zhonghua Nan Ke Xue; 2003 Nov; 9(8):563-5, 568. PubMed ID: 14689882
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lung cancer screening gets risk-specific.
    Peres J
    J Natl Cancer Inst; 2013 Jan; 105(1):1-2. PubMed ID: 23257155
    [No Abstract]   [Full Text] [Related]  

  • 6. Efficacy vs effectiveness in prostate-specific antigen screening.
    Albertsen PC
    J Natl Cancer Inst; 2010 Mar; 102(5):288-9. PubMed ID: 20142583
    [No Abstract]   [Full Text] [Related]  

  • 7. Re: Prostate-specific antigen: a misused and maligned prostate cancer biomarker.
    Hamilton RJ; Platz EA; Freedland SJ
    J Natl Cancer Inst; 2009 Apr; 101(8):611-2. PubMed ID: 19351913
    [No Abstract]   [Full Text] [Related]  

  • 8. Invited commentary: Prostate cancer: doing less might be more. Comment on "Severity of comorbidity and non-prostate cancer mortality in men with early-stage prostate cancer".
    Ablin RJ; Sartor O; Bennett CL
    Arch Intern Med; 2010 Aug; 170(15):1397-9. PubMed ID: 20696969
    [No Abstract]   [Full Text] [Related]  

  • 9. The cautionary tale of PSA testing.
    Hoffman RM; Zeliadt SB
    Arch Intern Med; 2010 Jul; 170(14):1262-3. PubMed ID: 20660847
    [No Abstract]   [Full Text] [Related]  

  • 10. Screening for prostate cancer - will we ever know?
    Adolfsson J
    Acta Oncol; 2010 Apr; 49(3):275-7. PubMed ID: 20397764
    [No Abstract]   [Full Text] [Related]  

  • 11. Prostate cancer: screening and early detection.
    Tariman JD
    Adv Nurse Pract; 2006 Sep; 14(9):20. PubMed ID: 16972436
    [No Abstract]   [Full Text] [Related]  

  • 12. Prostate cancer screening; is this a teachable moment?
    Brawley OW
    J Natl Cancer Inst; 2009 Oct; 101(19):1295-7. PubMed ID: 19720970
    [No Abstract]   [Full Text] [Related]  

  • 13. [Detection of prostate cancer: yes or no?].
    Van Cangh PJ
    Bull Mem Acad R Med Belg; 2006; 161(3-4):159-69. PubMed ID: 17172224
    [No Abstract]   [Full Text] [Related]  

  • 14. A risk-stratified approach to prostate-specific antigen screening.
    Keto CJ; Freedland SJ
    Eur Urol; 2011 Apr; 59(4):506-8. PubMed ID: 21292387
    [No Abstract]   [Full Text] [Related]  

  • 15. Is screening for prostate cancer the current gold standard?--"no".
    Kramer BS; Gohagan JK; Prorok PC
    Eur J Cancer; 1997 Mar; 33(3):348-53. PubMed ID: 9155515
    [No Abstract]   [Full Text] [Related]  

  • 16. Re: The prostate specific antigen era in the United States is over for prostate cancer: what happened in the last 20 years?
    Rosser CJ; Parker A
    J Urol; 2005 Sep; 174(3):1154-5; author reply 1155-6. PubMed ID: 16094093
    [No Abstract]   [Full Text] [Related]  

  • 17. Application of prostate-specific antigen in prostate cancer.
    Liang SL
    MLO Med Lab Obs; 2008 Oct; 40(10):54, 56-7. PubMed ID: 18988558
    [No Abstract]   [Full Text] [Related]  

  • 18. Early diagnosis of prostate cancer: the continuing debate on the impact on mortality.
    Höltl W; Lunglmayr G
    Wien Klin Wochenschr; 2005 Jul; 117(13-14):440-1. PubMed ID: 16091868
    [No Abstract]   [Full Text] [Related]  

  • 19. Controversy over prostate-specific antigen screening has shifted from mortality to overtreatment issues.
    Ito K
    Int J Urol; 2009 Sep; 16(9):711-12. PubMed ID: 19777638
    [No Abstract]   [Full Text] [Related]  

  • 20. Is additional testing necessary in men with prostate-specific antigen levels of 1.0 ng/mL or less in a population-based screening setting? (ERSPC, section Rotterdam).
    Roobol MJ; Roobol DW; Schröder FH
    Urology; 2005 Feb; 65(2):343-6. PubMed ID: 15708050
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.